ELIZABETH WIMMER: Open Payments
NPI 1619532108 · SAN CARLOS, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$960 in 39 payments from 10 companies in 2025. Trend: 2023 $0 · 2024 $247 · 2025 $960
Food & beverage: $960
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 17 | $258 |
| Madrigal Pharmaceuticals | 4 | $238 |
| Lilly USA, LLC | 4 | $120 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $99 |
| Janssen Biotech, Inc. | 3 | $72 |
| Ardelyx, Inc. | 2 | $56 |
| Boston Scientific Corporation | 1 | $41 |
| Celltrion USA Inc. | 1 | $33 |
| Phathom Pharmaceuticals, Inc. | 2 | $24 |
| Intercept Pharmaceuticals, Inc. | 1 | $19 |
Products named: REZDIFFRA, LINZESS, OMVOH, XIFAXAN, CREON, TREMFYA, IBSRELA, VIBERZI.
Industry payments across CA — which companies pay providers there.
